HIV vaccine research is moving through a changing prevention landscape, with scientists studying viral escape, bnAb combinations, mRNA-based approaches and AI-supported vaccine design.
World AIDS Vaccine Day, also known as HIV Vaccine Awareness Day, is observed each year on May 18.
The International AIDS Society shared the theme of World AIDS Vaccine Day 2026, “Rethink. Rebuild. Rise.” The theme reflects a perspective shift across the global HIV response, including funding uncertainty, shifting policy environments and the need to protect science, community-led systems and sustained collaboration.
Under Pressure: HIV Vaccine Research in Europe
Antiretroviral therapy and PrEP have changed HIV prevention and treatment. In June 2025, the FDA approved Gilead’s Yeztugo (lenacapavir), a twice-yearly injectable pre-exposure prophylaxis (PrEP) option to reduce the risk of sexually acquired HIV in adults and adolescents who weigh at least 35 kg.
HIV prevention has seen progress in recent years. But access to testing, prevention and long-term care remains uneven.
In Europe, the broader HIV response is showing strain. According to the International AIDS Society, Europe is off track on key HIV targets, with new HIV acquisitions rising, AIDS-related deaths increasing and viral suppression below target levels.
Get industry leading pharma and biotech news, events and expert insights delivered to your inbox.
A PLOS Global Public Health essay noted that the recent discontinuation of four major HIV vaccine efficacy studies in Europe has raised concern about whether the field can sustain long, expensive vaccine trials.
European Commission funding for HIV vaccine R&D declined from more than around $17.76 million (€15 million) in 2009 to approximately $10.58 million (€9 million) in 2020, and has since become far less visible in Horizon Europe. Without dedicated funding and a coordinated European research network, the authors warned, Europe-led HIV vaccine R&D risks losing expertise and future contribution to the field.
Europe could also lose research infrastructure and scientific expertise built through years of work in immunogen design, vaccine platforms, structural biology and clinical testing.
How Broadly Neutralizing Antibodies (bnAbs) Stack Up in HIV Vaccine Research
HIV vaccine research is difficult partly because the virus can find different ways to escape immune pressure.
Broadly neutralizing antibodies, or bnAbs, are rare immune proteins first identified in some people living with HIV that can recognize and block many HIV strains. Vaccine researchers are studying ways to guide B cells toward producing these antibodies.
A study published in Nature Microbiology showed that HIV can also develop resistance to individual bnAbs. The study tested two bnAbs in clinical development, 3BNC117 and 10-1074, across diverse HIV-1 strains. Across 7,776 selection experiments, researchers found that escape pathways varied widely by strain.
In many cases, one amino acid change was enough to confer resistance. Future vaccine and antibody strategies will likely need carefully selected combinations that make viral escape harder.
South Africa-Based Trials Test New HIV Vaccine Designs
In South Africa, IAVI, a global nonprofit involved in HIV vaccine research, is running IAVI G004, a Phase I clinical trial. The trial is part of the IAVI/Scripps Research HIV vaccine development strategy, which focuses on guiding specific B cells toward bnAbs.
In January 2026, IAVI announced the first vaccinations in IAVI G004. The study is testing three experimental HIV vaccine immunogens developed by IAVI and Scripps Research and delivered on Moderna’s mRNA platform. It is enrolling 96 healthy adults living without HIV across six clinical sites in South Africa and will examine safety, immune responses and dose levels.
Another South Africa-based study, BRILLIANT 011, launched as a first-in-human HIV vaccine trial in Cape Town. The trial is testing two vaccine components, BG505 GT1.1 and 426c.Mod.Core-C4b, with the SMNP adjuvant. The trial is part of an African-led HIV vaccine research effort focused on strains circulating in Southern Africa.
AI Adds Speed to HIV Vaccine Design
Scripps Research is using AI and high-performance computing to support HIV vaccine design. In November 2025, its scientists received $1.1 million from the Scripps Consortium for HIV/AIDS Vaccine Development to advance AI modeling for HIV vaccine research.
The institute is aiming to analyze large volumes of antibody and vaccine design data faster, reduce bottlenecks and help researchers identify stronger vaccine candidates. The Scripps team plans to use AI to evaluate vaccine-induced antibodies, model how they interact with HIV at the molecular level and refine follow-up vaccine designs.
FAQs
Why is HIV so hard to make a vaccine against?
HIV changes quickly and has many global variants. It also has a heavily shielded surface, which makes it harder for the immune system to recognize the right viral targets.
How is an HIV vaccine different from PrEP?
PrEP uses medicine to help prevent HIV before exposure. A vaccine would aim to train the immune system to recognize HIV and respond before infection can take hold.
Why do early HIV vaccine trials often focus on immune responses?
Early trials usually assess whether a vaccine approach is safe and whether it can elicit the intended immune response. They are not usually designed to prove protection from HIV infection.
If you want your company to be featured on Xtalks.com, please email [email protected].
Join or login to leave a comment
JOIN LOGIN